anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The C-reactive protein-albumin-lymphocyte (CALLY) index, which integrates albumin, lymphocytes, and C-reactive protein levels, has emerged as a novel method to assess nutritional and inflammatory statuses in patients. This study examined the correlation between the CALLY index and sarcopenia risk using two cohorts: 1804 community dwellers from the NHANES database in the United States and 139 patients from the Department of Gerontology at Kunshan Hospital, China. In the US community cohort, RCS curve analysis was used to examine the non-linear relationship between inflammatory/nutritional markers and sarcopenia, subgroup analysis was also conducted. Logistic regression was employed to evaluate the association between the CALLY index and the risk of sarcopenia in both cohorts. Results demonstrated a significant non-linear relationship between the CALLY index and the risk of sarcopenia (P < 0.001). Elevated levels of the CALLY index are independently linked to a decreased risk of sarcopenia in both community residents (OR = 0.35, 95% CI 0.20-0.57, Q3 CALLY index and OR = 0.26, 95% CI 0.11-0.56, Q4 CALLY index) and hospitalized patients (OR = 0.35, 95% CI 0.12-0.96). This finding identified low CALLY index as a conveniently measurable parameter, serving as a nutritional and inflammatory risk factor for sarcopenia.
Compositions and methods of non-invasive diagnosis are provided. The imaging agents include a linking groups and a reactive entity capable of reaction with a reactive functionality to form a covalent bond therewith. The imaging agents may be in the form of a bifunctional anchor molecule. The bifunctional anchor molecules have a functional group capable of activation which, when activated, may form a covalent bond with a reactive functionality on a target protein present in the mammalian vascular system, thereby “anchoring” the molecule to that target protein. The bifunctional anchors are also conjugated, either directly or indirectly, to a diagnostic agent of interest which provides the ability to diagnostically and non-invasively image the mammalian vascular space. Vascular targets include both cellular- and noncellular-associated proteins present in the mammalian vascular system. The methods find use for numerous applications arising from the ability to diagnostically image the mammalian vascular space over an extended period of time or to preferentially diagnostically image only a specific cell type or compartment of the mammalian vascular space.
PURPOSE:To enable efficient mass-production in an industrial scale by infecting a Panax ginseng with Agrobacterium rhizogenes and culturing the resultant transformed root in a turbineincorporated culture tank while exchanging a culture medium every one week. CONSTITUTION:A Panax ginseng such as Panax japanicum is infected with Agrobacterium rhizogenes by the direct vaccination method, etc., and then cultured in a liquid medium such as Murashige-Skoog medium and the resultant grown transformed root is used as a seed for jar culture using a turbine- incorporated culture tank. The above-mentioned culture is carried out while exchanging the culture medium for a fresh culture medium every a certain period, e.g. every one week on the way of the culture. Decrease in growth rate on the way of the culture can be prevented by the above-mentioned method and a remarkably high final density can be realized. Stable growth of cells, remarkable reduction of culture period, increase in cell density in the culture solution and improvement of saponin productivity are possible thereby.
BACKGROUND: While transradial access is favored for cardiac catheterization, the radial artery (RA) is increasingly preferred for coronary artery bypass grafting. Whether the RA is suitable for use as a graft following instrumentation for transradial access remains uncertain.
METHODS: Consecutive patients from 2015 to 2019 who underwent coronary artery bypass grafting using both the left and right RAs as grafts were included. Instrumented RAs underwent careful preoperative assessment for suitability. The clinical analysis was stratified by whether patients received an instrumented RA graft (instrumented versus noninstrumented groups). Eligible patients with both instrumented and noninstrumented RAs underwent computed tomography coronary angiography to evaluate graft patency. The primary outcome was a within-patient paired analysis of graft patency comparing instrumented to noninstrumented RA grafts.
RESULTS: Of the 1123 patients who underwent coronary artery bypass grafting, 294 had both the left and right RAs used as grafts and were included. There were 126 and 168 patients in the instrumented and noninstrumented groups, respectively. Baseline characteristics and perioperative outcomes were comparable. The rate of major adverse cardiac events at 2 years following coronary artery bypass grafting was 2.4% in the instrumented group and 5.4% in the noninstrumented group (hazard ratio, 0.44 [95% CI, 0.12-1.61]; P=0.19). There were 50 patients included in the graft patency analysis. At a median follow-up of 4.3 (interquartile range, 3.7-4.5) years, 40/50 (80%) instrumented and 41/50 (82%) noninstrumented grafts were patent (odds ratio, 0.86 [95% CI, 0.29-2.52]; P>0.99). No significant differences were observed in the luminal diameter or cross-sectional area of the instrumented and noninstrumented RA grafts.
CONCLUSIONS: There was no evidence found in this study that RA graft patency was affected by prior transradial access, and the use of an instrumented RA was not associated with worse outcomes in the exploratory clinical analysis. Although conduits must be carefully selected, prior transradial access should not be considered an absolute contraindication to the use of the RA as a bypass graft.
REGISTRATION: URL: https://www.anzctr.org.au/; Unique identifier: ACTRN12621000257864.
The invention discloses a medicine for eliminating damages of tannins to liver. The medicine comprises Chinese gall, Medicine Terminalia Fruit, garlic, licorice root, honeysuckle flower, wild chrysanthemum flower, rheum officinale, Cortex Fraxini, Herba Houttuyniae, hawthorn fruit, Rhizoma Coptidis, Radix Scutellariae, Amur Corktree Bark, isatis root, Rhizoma Alismatis, Chinese angelica, dried orange peel, Radix Asparagi, Weeping Forsythia, Artemisia carvifolia, dark plum, pangolin, fortune paulownia flower, Cayratia japonica, Solanum lyratum Thunb, Ligusticum wallichii and Panax Notoginseng. The medicine for eliminating damages of tannins to liver can be used for treating turtle putrid skin disease, and Chinese gall and Medicine Terminalia Fruit are decocted in an ethanol solution to reduce the extraction rate of tannins. The above traditional Chinese medicinal prescription can be used for the putrid skin disease, and has a substantial curative effect and no side effects. Garlic and other heavy taste materials are used, and are reasonably combined with other medicines in order to realize taste removal and curative effect remaining purposes. Iron trichloride reacts with hydrolysable tannins to generate precipitates. The medicine can be combined with western antibiotics, and sodium bicarbonate and other components can be added to further improve the curative effect.
Optimal dosage should be established by individual titration of the components.

Edema in adults (congestive heart failure, hepatic cirrhosis, or nephrotic syndrome). The usual maintenance dose of spironolactone and hydrochlorothiazide tablets is 100 mg each of spironolactone and hydrochlorothiazide daily, administered in a single dose or in divided doses, but may range from 25 mg to 200 mg of each component daily depending on the response to the initial titration. In some instances it may be desirable to administer separate tablets of either spironolactone or hydrochlorothiazide in addition to spironolactone and hydrochlorothiazide tablets in order to provide optimal individual therapy.

The onset of diuresis with spironolactone and hydrochlorothiazide tablets occurs promptly and, due to prolonged effect of the spironolactone component, persists for two to three days after spironolactone and hydrochlorothiazide tablets are discontinued.

Essential hypertension. Although the dosage will vary depending on the results of titration of the individual ingredients, many patients will be found to have an optimal response to 50 mg to 100 mg each of spironolactone and hydrochlorothiazide daily, given in a single dose or in divided doses.

Concurrent potassium supplementation is not recommended when spironolactone and hydrochlorothiazide tablets are used in the long-term management of hypertension or in the treatment of most edematous conditions, since the spironolactone content of spironolactone and hydrochlorothiazide tablets is usually sufficient to minimize loss induced by the hydrochlorothiazide component.
Obesity has become a major risk of global public health. SMEK1 is also known as a regulatory subunit of protein phosphatase 4 (PP4). Both PP4 and SMEK1 have been clarified in many metabolic functions, including the regulation of hepatic gluconeogenesis and glucose transporter gene expression in yeast. Whether SMEK1 participates in obesity and the broader metabolic role in mammals is unknown. Thus, we investigated the function of SMEK1 in white adipose tissue and glucose uptake. GWAS/GEPIA/GEO database was used to analyze the correlation between SMEK1 and metabolic phenotypes/lipid metabolism-related genes/obesity. Smek1 KO mice were generated to identify the role of SMEK1 in obesity and glucose homeostasis. Cell culture and differentiation of stromal-vascular fractions (SVFs) and 3T3-L1 were used to determine the mechanism. 2-NBDG was used to measure the glucose uptake. Compound C was used to confirm the role of AMPK. We elucidated that SMEK1 was correlated with obesity and adipogenesis. Smek1 deletion enhanced adipogenesis in both SVFs and 3T3-L1. Smek1 KO protected mice from obesity and had protective effects on metabolic disorders, including insulin resistance and inflammation. Smek1 KO mice had lower levels of fasting serum glucose. We found that SMEK1 ablation promoted glucose uptake by increasing p-AMPKα(T172) and the transcription of Glut4 when the effect on AMPK-regulated glucose uptake was due to the PP4 catalytic subunits (PPP4C). Our findings reveal a novel role of SMEK1 in obesity and glucose homeostasis, providing a potential new therapeutic target for obesity and metabolic dysfunction.NEW & NOTEWORTHY Our study clarified the relationship between SMEK1 and obesity for the first time and validated the conclusion in multiple ways by combining available data from public databases, human samples, and animal models. In addition, we clarified the role of SMEK1 in glucose uptake, providing an in-depth interpretation for the study of its function in glucose metabolism.
Absorption: Cephalexin is acid stable and may be given without regard to meals. Following doses of 250 mg, 500 mg, and 1 g, average peak serum levels of approximately 9, 18, and 32 mcg/mL, respectively, were obtained at 1 hour. Serum levels were detectable 6 hours after administration (at a level of detection of 0.2 mcg/mL). 

Distribution: Cephalexin is approximately 10% to 15% bound to plasma proteins.

Excretion: Cephalexin is excreted in the urine by glomerular filtration and tubular secretion. Studies showed that over 90% of the drug was excreted unchanged in the urine within 8 hours. During this period, peak urine concentrations following the 250 mg, 500 mg, and 1 g doses were approximately 1000, 2200, and 5000 mcg/mL respectively. 

Drug Interactions  
In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.
Group 1 will undergo induction using a transcervical Foley catheter (silicone, size 18F with 30ml balloon) which will remain until active labour starts, the Foley catheter falls out, or 12 hours have elapsed. If the Foley catheter falls out within 12h, membranes will be ruptured and/or oxytocin infusion started. If the Foley catheter does not fall out within 12h, it will be removed at 12h and oxytocin commenced with an artificial rupture of membrane when possible. If labour has still not commenced after 24 hours, they will be deemed to have a 'failed induction' and the decision on further management will be made by the clinical team (their choice could include the use of misoprostol, repeat Foley catheter, dinoprostone, caesarean section or delay as deemed appropriate).
Glycoprotein nonmetastatic melanoma protein B (GPNMB) is a type I transmembrane protein initially identified in nonmetastatic melanomas and has been associated with human heart failure; however, its role in cardiac injury and function remains unclear. Here we show that GPNMB expression is elevated in failing human and mouse hearts after myocardial infarction (MI). Lineage tracing and bone-marrow transplantation reveal that bone-marrow-derived macrophages are the main source of GPNMB in injured hearts. Using genetic loss-of-function models, we demonstrate that GPNMB deficiency leads to increased mortality, cardiac rupture and rapid post-MI left ventricular dysfunction. Conversely, increasing circulating GPNMB levels through viral delivery improves heart function after MI. Single-cell transcriptomics show that GPNMB enhances myocyte contraction and reduces fibroblast activation. Additionally, we identified GPR39 as a receptor for circulating GPNMB, with its absence negating the beneficial effects. These findings highlight a pivotal role of macrophage-derived GPNMBs in post-MI cardiac repair through GPR39 signaling.
In Arm A, the dose-escalation cohort, there will be 3 cohorts of ascending MRgFUS power/energy dose combinations with a fixed SONALA-001 dose and fixed surgical time. Arm A will determine the power/energy dose combination for Arm B.
PROBLEM TO BE SOLVED: To obtain a body-washing agent which promotes the metabolisms of skin and does not need a rinse, when used for washing hair. SOLUTION: An ionized soap 1 is formed in a shape having both the rectangular plate surfaces, round corners and slightly projected central portions. The size of the soap is 60 mm×80 mm×20 mm. The ionized soap 1 is produced by saponifying natural oils or fats, salting out the saponification products, adding ionized sodium chloride to the obtained soap layer, pouring the mixture in a mold, and then cooling and solidifying the molded product. The ionized sodium chloride is ionized by a method proposed by the applicants of the present application. Since the ionized soap 1 contains minus ions in a large amount, the minus ions are supplied to a used site.
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive treatment and imaging, and may undergo blood sample collection as in arm C.
The purpose of this project is to conduct an observational study on the efficacy and safety of entrectinib in real-world patients with ROS1-positive NSCLC who have received entrectinib treatment, while exploring the mechanism of entrectinib's brain protection and resistance mechanism. Because this study is a non-interventional study, it will not interfere with your usual treatment. However, your medical data will be analyzed, and the results will help improve future treatment options for ROS1 positive NSCLC patients and improve their quality of life.This study was divided into three cohorts. Cohort 1: For patients with advanced ROS1-positive NSCLC who met the inclusion criteria and had not received TKI treatment, they were treated with entrectinib until disease progression or intolerance (N=15); Cohort 2: For patients with advanced ROS1-positive NSCLC who met the inclusion criteria and had received first-generation ROS1 TKI treatment with disease progression on crizotinib, they were treated with entrectinib until disease progression or intolerance (N=15); Cohort 3: For patients with ROS1-positive NSCLC who had failed multiple lines of treatment, they were treated with entrectinib until disease progression or intolerance (N=10). Regular follow-up was conducted and relevant clinical data were recorded, followed by Cox regression analysis and survival analysis. The information that needs to be recorded includes baseline and treatment genetic testing, demographic information, anti-cancer history, and concomitant medication use, as well as the use of study drugs and adverse events during treatment visits, survival and subsequent drug use after discharge, and the follow-up frequency consistent with clinical practice. Subjects are eligible for a complimentary NGS test upon the development of entrectinib resistance.
The method for treating balanoposthitis in the childrencomprises the blunt separation of the synechias between the internal layer of the prepuce and glans penis followed by the treatment of the preputial cavity with the antiseptic solution. The glans penis is left within the preputial sac and the biologically active additive "Tea Tree Oil" is injected by the disposable 5-ml syringe without the needle, the cannula of the syringe being clasped tightly by the prepuce providing for sealing the preputial sac. "Tea Tree Oil" is used as 2.0-10.0% aqueous and oil solution in a volume 3-4 ml. The solution is administered until the prepuce is inflated. Then the cannula of the syringe is withdrawn and the end of the prepuce is held closed for 2-3 minutes. The instillation is performed once a day, 1-3 instillations for a course of the treatment with the accompanying massage of the preputial sac.
OBJECTIVES: I. Determine the safety and toxicity of motexafin gadolinium (PCI-0120) when administered concurrently with radiotherapy in patients with locally advanced unresectable pancreatic or biliary tree tumors. II. Assess the pharmacokinetics of this regimen in these patients. III. Assess tumor uptake of PCI-0120 (by MRI signal characteristics) in these patients. IV. Determine the maximum tolerated dose of PCI-0120 in these patients. V. Determine the objective response (by radiologic criteria) in patients treated with this regimen.

OUTLINE: This is a multicenter, dose-escalation study of motexafin gadolinium (PCI-0120). Patients receive PCI-0120 IV over 15 minutes 3 times weekly concurrently with external beam radiotherapy (EBRT) 5 days a week for 5.5 weeks. After completion of EBRT and PCI-0120, patients may undergo radiotherapy boost for 5 consecutive days. Cohorts of 3-6 patients receive escalating doses of PCI-0120 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 6-12 patients are treated at the recommended phase II dose. The recommended phase II dose is defined as the dose immediately preceding the MTD. Patients are followed at 4 weeks.

PROJECTED ACCRUAL: A total of 18-21 patients will be accrued for this study.
PURPOSE:To provide the titled preparation containing L-proline and an epidermis growth factor (EGF) as active components. CONSTITUTION:L-proline (Pro) (a commercially available Pro can be used) and EGF (preferably a human-originated EGF such as urogastrone, etc.) are used as active components of the titled drug preparation for hepatic disease. The Pro is used excess to EGF, e.g. about 750-120,000pts.wt. preferably 1,500-12,000pts.wt. of Pro per 1pt.wt. of EGF. There is no particular restriction in the method of administration. It is preferably administered at a rate of 0.1-10g of the total active components daily in the form of a drug preparation containing 1-80wt% active components. The agent promotes the regeneration or renewal of damaged hepatic cells or tissues, restores the physiological activity of the cells, etc., and drastically normalizes and recovers the hepatic functions.
A pharmaceutical composition, a combination product including the composition and a method of manufacturing the composition. The composition includes a particulate complex of API bound with a crosslinked polysaccharide micro sponge. The combination product includes a dosage form of the particulate complex within a container. The amount of the particulate complex is selected to provide a defined dose of the API. The formulation may be heated within the container by a vaporizer device, vaporizing the API and dissociating the API from the micro sponge as vapour, which passes through apertures in the container facilitating administration of the API by inhalation of the vapour. The apertures are sized to facilitate passage of the vapour but prevent passage the particulate complex. The API may be hydrophobic such as phytocannabinoids or hydrophilic such as nicotine. The pharmaceutical composition may be manufactured by driving binding of the API to the micro sponge in solution.
CNS stimulants, including dexmethylphenidate hydrochloride tablets, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; however, sequelae have included digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud’s phenomenon, were observed in post-marketing reports and at the therapeutic dosages of CNS stimulants in all age groups throughout the course of treatment. Signs and symptoms generally improved after dosage reduction or discontinuation of the CNS stimulant. 

Careful observation for digital changes is necessary during dexmethylphenidate hydrochloride treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for dexmethylphenidate hydrochloride-treated patients who develop signs or symptoms of peripheral vasculopathy.
Pregnancy Category D 

Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue valsartan and hydrochlorothiazide as soon as possible. [see USE IN SPECIFIC POPULATIONS (8.1)]. 

Intrauterine exposure to thiazide diuretics is associated with fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in adults.